论文部分内容阅读
目的对青海省新发现的HIV-1抗体阳性的感染者进行首次CD4+T淋巴细胞绝对值进行测定,了解其免疫状况及疾病进展状况。方法对采集的168份全血样本以四色荧光抗体进行标记,用流式细胞仪进行CD4+T淋巴细胞绝对数的检测,统计分析其测定值。结果 168例HIV感染者的CD4+T淋巴细胞均数为(323.92±198.66)个/μL,CD4+T淋巴细胞计数≤200个/μL的占31.55%,201～350个/μL的占29.17%,351～500个/μL的占23.81%,>500个/μL的占15.48%。不同性别间CD4+T淋巴细胞均值的差异无统计学意义(t=1.67,P>0.05);4种不同感染途径的CD4+T淋巴细胞均值的差异有统计学意义(F=3.52,P<0.05),同性性传播组的数值明显高于输血液组;不同年龄组间CD4+T淋巴细胞均值的差异有统计学意义(F=7.52,P<0.05),18～30岁年龄组的数值最高。结论青海省HIV感染者的CD4+T淋巴细胞免疫水平普遍偏低,60.71%感染者已进入艾滋病期,应对其定期进行CD4+T淋巴细胞检测,监测疾病进展和及时给予抗病毒治疗,以把握治疗的最佳时期。
Objective To determine the absolute value of the first CD4 + T lymphocytes in newly discovered HIV-1 antibody-positive patients in Qinghai Province to understand their immune status and disease progression. Methods A total of 168 whole blood samples were collected and labeled with four - color fluorescent antibody. The absolute number of CD4 + T lymphocytes was detected by flow cytometry. The measured values were statistically analyzed. Results The average number of CD4 + T lymphocytes in 168 HIV-infected patients was (323.92 ± 198.66) / μL, the number of CD4 + T lymphocyte counts ≤200 cells / μL accounted for 31.55%, and the proportion of 201-350 cells / μL was 29.17% , Accounting for 23.81% for 351 to 500 cells / μL and 15.48% for> 500 cells / μL. There was no significant difference in mean of CD4 + T lymphocytes between different genders (t = 1.67, P> 0.05). The mean of CD4 + T lymphocytes in four different infection ways was statistically significant (F = 3.52, P < 0.05), and the values of homosexual transmission group were significantly higher than that of transfusion group. The mean of CD4 + T lymphocyte in different age groups was statistically significant (F = 7.52, P <0.05), and the value of 18-30 age group highest. Conclusion The level of CD4 + T lymphocyte immunization in HIV-infected persons in Qinghai Province is generally low, and 60.71% of the infected people have entered the AIDS phase. The CD4 + T lymphocytes should be detected periodically to monitor the progress of the disease and timely give antiviral therapy. The best period of treatment.